Please login to the form below
CAR-T therapy
This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
Gilead company Kite has unveiled positive results for its CAR-T therapy Yescarta in the second-line setting for relapsed or refractory large B-cell lymphoma (LBCL). . ... The CAR-T therapy also met key secondary endpoints of complete response rate and
Latest news
-
CHMP recommends eight new medicines for EU approval
BMS’ CAR T therapy Abecma and BioMarin’s dwarfism drug Voxzogo among positive recommendations. ... The positive opinions include Bristol Myers Squibb’s CAR T therapy Abecma (idecabtagene vicleucel) as a potential new treatment for highly refractory
-
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
The combined strength of Kite’s leadership in CAR T-cell therapies and our cutting-edge iPSC platform will potentially accelerate Shoreline’s timeline to the clinic, expand our pipeline opportunities ... Xanthopoulos, co-founder, chairman and chief
-
BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
Bristol Myers Squibb (BMS) has reported positive topline results from a phase 3 study of CAR-T therapy Breyanzi as a second-line treatment for relapsed or refractory large B-cell ... The CAR-T therapy also met key secondary endpoints of complete
-
FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy
CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months. ... J&J initially licensed cilta-cel from Legend in December 2017 to develop and commercialise the CAR T therapy for an upfront
-
Sanofi pays $160m upfront to acquire Tidal Therapeutics
such as chimeric antigen receptor (CAR)-expressing T-cells. ... We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population,” said Frank Nestle, global head of
CHMP recommends eight new medicines for EU approval
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy
Sanofi pays $160m upfront to acquire Tidal Therapeutics
More from news
Approximately 19 fully matching, plus 97 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Bristol Myers Squibb and bluebird bio’s idecabtagene vicleucel CAR-T therapy further emphasise this point. ... A crucial challenge faced by cell and gene therapy developers is the necessity to balance clinical considerations with logistical ones such
-
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
EBCs also demonstrate positive data and are bringing novel therapies to market in complex areas of medicine, including gene therapy, CAR T-cell therapy and rare diseases. ... These visuals got the message across in an engaging, novel and efficient manner
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Examining three entirely different approaches to CAR-T therapy, it is possible to see just how much space there is for this exciting sector, therefore displaying the case for continued investment. ... Innovative CAR-T therapy demonstrates the depth of
-
Surviving cancer: a new era for patients
Chimeric antigen receptor T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy consists of engineering receptors in the body that selectively interact with cancer cells, inducing cell death without affecting ... CAR-T therapy has potential
-
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... It now has more than 300 CAR-T clinical trials underway and collaboration with European and
Keeping up with the developing regulatory requirements for gene and cell therapies
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Surviving cancer: a new era for patients
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
In the precision medicine era, the line between products and services is blurred
In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to ... However, due to its novelty, it was difficult to access patients who have
-
The impossible launch
SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.
-
Understanding the evolving CAR-T market
In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.
-
Precision paediatrics: Treating patients with CAR-T
Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.
-
Highlights in haematologic malignancy from ASH 2018
The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Understanding the ‘real world’ starts and ends with the patient
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Sanofi raises profit forecast following positive Q2 results
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Reducing primary care antibiotic use may not be enough to counter antimicrobial resistance
- SoftBank buys $5bn stake in Roche
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Amanda Pritchard becomes NHS England’s first female chief executive
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
